Abstract 708P
Background
Next generation sequencing (NGS) has become widely available but molecular profiling guided therapy (MGT) has not been established in the real world due to a lack of available therapies and expertise to interpret and match treatment in Korea.
Methods
Patients with advanced solid tumors without remaining standard treatment were enrolled. Virtual, central molecular tumor boards (cMTB) reviewed patients’ NGS reports and recommended clinical trials or investigational medicinal products (IMPs) as previously described (https://doi.org/10.1016/j.esmoop.2022.100653). Primary variable was to assess the proportion of patients with actionable genomic alterations and patients receiving MGT as MTB recommendations. Other variables were duration of treatment (DoT), overall response rate (ORR), disease control rate (DCR) and safety.
Results
From Feb 2021 to Feb 2022, 198 patients were enrolled. Median time from case submission to MTB discussion was 7 days (range, 2-20) and concordance rate between pre-MTB physicians’ choice and MTB recommendations were 60.1% (119/198). A total of 107 (54.0%) received IMPs based on MTB decision (32, TE; 21, AZ; 14, TP; 13, BE; 8, AP; 6, CA; 5, DT; 4, AL; 3, EL; 1, BV). ORR and DCR were 13.3% (1 CR, 9 PR, 45 SD, and 20 PD), and 73.3%. DoT was 3.6 months (95% CI, 2.8-5.0) and 4 months DoT rate (4MDoTR) was 45.5%. DoT>12 months were observed in 10 (9.3%). TE showed a durable DoT, regardless of ERBB2 amplification and mutation (5.8 and 4.0 months), previous exposure of anti-HER2 targeted agents (4.0(No) vs. 5.4 months (Yes)), and high (6>) vs. low (6<) copy number variation (4.0 and 8.0 months).
Table: 708P
| IMPs | ORR | DCR | 4MDoTR | DoT(months) |
| Alectinib (AL) | 33.3% | 33.3% | 50.0% | 3.4 |
| Alpelisib (AP) | 50.0% | 50.0% | 42.9% | 1.4 |
| Atezolizumab (AZ) | 21.4% | 57.1% | 30.0% | 1.9 |
| Bevacizumab (BV) | 0.0% | 100.0% | 100.0% | 8.3 |
| Bevacizumab + erlotinib (BE) | 9.1% | 54.5% | 33.3% | 3.4 |
| Capecitabine (CA) | 0.0% | 100.0% | 0.0% | 1.6 |
| Dabrafenib + trametinib (DT) | 50.0% | 100.0% | 60.0% | 6.9 |
| Erlotinib (EL) | 0.0% | 100.0% | 66.7% | 6.5 |
| Trastuzumab and pertuzumab (TP) | 0.0% | 100.0% | 57.1% | 4.6 |
| Trastuzumab emtansine (TE) | 8.3% | 75.0% | 56.7% | 4.2 |
| All | 13.3% | 73.3% | 45.5% | 3.6 |
Conclusions
KOSMOS suggested the feasibility of nationwide cMTB guided MGT and also showed modest ORR, and a promising DCR in heavily pre-treated patients. KOSMOS-II (NCT05525858) is currently underway to confirm this in larger number of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Korean Society of Medical Oncology, Korean Cancer Study Group.
Funding
Roche. And this study was supported by the National R&D Program for Cancer Control through the National Cancer Center(NCC) funded by the Ministry of Health&Welfare, Republic of Korea (HA22C0052).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17